Eli Lilly will acquire all shares of Sigilon Therapeutics for $34.6 million to gain access to its cell therapies for diabetes. Under the terms of the deal, Lilly will pay Siglion $34.6 million up front with the potential pay-out totalling to $309.6 million, dependent on specific regulatory and developmental milestones. “Despite significant advancement in treatment for people living with type 1 diabetes, many continue to live with a high disease burden every day,” said Ruth Gimeno, group vice president, diabetes, obesity…